Respiratory
Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Note: This webpage hosts content for general public as well as for healthcare professional and journalists & media professionals. To be able to see and access respective content you need to select your profession through the filter button on the right.
-
Ivan Blanarik
Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
-
Man with laptop
-
EURORDIS Black Pearl AWARDS
Scleroderma
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020